Kwanjoo Lee

Kwanjoo Lee

Auto-generated profile, based on publicly available information

Kwanjoo Lee

Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2023 in eClinicalMedicine
Verified
Journal Article
Open access
JHJong Woo Hahn
Jong Woo Hahn
HYHye Ran Yang
Hye Ran Yang
JMJin Soo Moon
Jin Soo Moon
JCJu Young Chang
Ju Young Chang
KLKwanjoo Lee
Kwanjoo Lee
DYDong Keon Yon
Dong Keon Yon
Autoimmune hepatitis (AIH) varies significantly in incidence and prevalence across countries and regions. We aimed to examine global, regional, and national trends in incidence and prevalence of AIH from 1970 to 2022. We conducted a thorough search of the PubMed/MEDLINE, Embase, CINAHL, Google Scholar, and Cochrane databases from database inception to August 9, 2023, using the search term “autoimmune hepatitis” in combination with “incidence,” “prevalence,” or “trend.” Only general population-based observational studies with larger samples sizes were considered for inclusion. Studies that recruited convenience samples, and those with fewer than 50 participants were excluded. Summary data were extracted from published reports. A random effects model was used and pooled estimates with 95% CI were used to calculate the incidence and prevalence of AIH. Heterogeneity was evaluated using the I2 statistic. The study protocol was registered with PROSPERO, CRD42023430138. A total of 37 eligible studies, encompassing more than 239 million participants and 55,839 patients with AIH from 18 countries across five continents, were included in the analysis. Global pooled incidence and prevalence of AIH were found to be 1.28 cases per 100,000 inhabitant-years (95% CI, 1.01–1.63, I2 = 99·51%; number of studies, 33; sample population, 220,673,674) and 15.65 cases per 100,000 inhabitants (95% CI, 13.42–18.24, I2 = 99·75%; number of studies, 26; sample population, 217,178,684), respectively. The incidence of AIH was greater in countries with high Human Development Index (>0.92), in North America and Oceania (compared with Asia), among females, adults (compared with children), and high latitude (>45°). Similar patterns in AIH prevalence were observed. Pooled AIH prevalence increased gradually from 1970 to 2019 (1970–1999; 9.95 [4.77–15.13], I2 = 95·58% versus 2015–2022; 27.91 [24.86–30.96], I2 = 99·32%; cases per 100,000 inhabitants). The overall incidence and prevalence of AIH, as well as some subgroup analyses of the studies, displayed asymmetry in the funnel plots, suggesting potential evidence of publication bias. AIH incidence and prevalence have increased significantly and exhibit substantial variation across regions worldwide. Further research is required to assess the incidence and prevalence of AIH, specifically in South America and Africa. 10.13039/501100003725 National Research Foundation of Korea .

2 March 2024 in United European Gastroenterology Journal
Verified
Journal Article
Open access
KLKwanjoo Lee
Kwanjoo Lee
SHSung Pyo Hong
Sung Pyo Hong
IYIn Kyung Yoo
In Kyung Yoo
AYAbdullah Özgür Yeniova
Abdullah Özgür Yeniova
JHJong Woo Hahn
Jong Woo Hahn
DYDong Keon Yon
Dong Keon Yon
Background: Achalasia poses a significant socioeconomic burden, yet global trends remain undocumented. This study aims to describe the worldwide trends in the incidence and prevalence of achalasia from 1925 to 2021 and explore their correlation with various factors through a comprehensive systematic review.Methods: We searched the PubMed/MEDLINE, Embase, and Cochrane databases from inception to 30 June 2023, to identify studies reporting the incidence or prevalence of achalasia in the general population. This study utilized pooled estimates with 95% confidence intervals (CI) to estimate the incidence and prevalence of achalasia, and conducted various subgroup analyses.Results: A total of 26 eligible studies covering approximately 269 million participants and 20,873 patients from 14 countries across five continents were included. Global pooled incidence and prevalence of achalasia were estimated to be 0.78 cases per 100,000 person‐years (95% CI, 0.64–0.93; number of studies, 26; sample population, 269,315,171) and 10.82 cases per 100,000 person‐years (95% CI, 8.15–13.48; number of studies, 14; sample population, 192,176,076), respectively. The incidence of achalasia was higher in Oceania (than Asia and Africa) and in adults (than children) after the introduction of the Chicago classification. Prevalence followed a similar pattern. The pooled incidence of achalasia showed an overall upward trend from 1925 to 2021 (1925–1999; 0.40 [0.32–0.49] vs. 2018–2021; 1.64 [1.33–1.95] cases per 100,000 person‐years).Conclusions: The incidence and prevalence of achalasia have notably increased, particularly with advancements in diagnosis, and show significant variation worldwide, despite the large heterogeneity within the sample population. Further studies are necessary to accurately assess the global incidence and prevalence of achalasia.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JHJong Woo Hahn
Jong Woo Hahn
SWSelin Woo
Selin Woo
JPJaeyu Park
Jaeyu Park
HLHyeri Lee
Hyeri Lee
HKHyeon Jin Kim
Hyeon Jin Kim
DYDong Keon Yon
Dong Keon Yon
Hahn JW, et al. J Korean Med Sci. 2024 Sep;39:e292. https://doi.org/10.3346/jkms.2024.39.e292

15 September 2026 in Gut and Liver
Verified
Journal Article
Open access
PDF file
KLKwanjoo Lee
Kwanjoo Lee
JSJun-young Seo
Jun-young Seo
Kwanjoo Lee, Jun-young Seo. Gut and Liver 2026;20:709-10. https://doi.org/10.5009/gnl260332

23 April 2020
Verified
Conference Paper
Closed access
WPWh Paik
Wh Paik
SYSw Yi
Sw Yi
JCJh Cho
Jh Cho
YKYt Kim
Yt Kim
KLKj Lee
Kj Lee
KCKorean Gastroenteropancreatic Neuroendocrine Tumor Registry Research Project of the Korean Society of Gastrointestinal Cancer
Korean Gastroenteropancreatic Neuroendocrine Tumor Registry Research Project of the Korean Society of Gastrointestinal Cancer
Aims Pancreatic neuroendocrine neoplasm (PNEN) represents heterogeneous biological behavior, and most of small PNENs 2 cm or less in size are known to show indolent feature. Thus, observation can be considered in selected cases according to the NCCN guideline, however, there is a lack of clinical evidence, and the criteria are vague. We evaluated the usefulness of EUS-guided fine needle biopsy in determination of treatment plan for small PNEN. Methods A total of 158 patients from 14 institutions with pathologically confirmed PNENs 2 cm or less in initial imaging were enrolled. The primary outcome was any event of metastasis or recurrence during follow up. Results The median age was 57.5 years (range, 22-84 years), and 86 patients (54%) were female. Eighteen patients (11%) had a tumor-related symptoms at initial diagnosis, and the median size of the tumor was 1.3 cm (range, 0.7-2.0 cm). The results of WHO classification were available in 147 patients: 126 patients (86%) with grade 1 and 21 patients (14%) with grade 2. Pathological diagnosis with EUS-guided aspiration biopsy was confirmed in 22 patients, and among them, identification of WHO classification was also available in 17 patients. Among six patients who underwent EUS-guided aspiration biopsy and surgery together, the concordance rate of WHO classification between two methods was 83% (5/6). A total of 142 patients (90%) underwent radical resection, and seven metastasis or recurrence (5%) were detected during follow up. WHO classification grade 2 was the only risk factor predicting metastasis or recurrence in univariate and multivariate analysis (HR 8.81, 95% CI 1.76-44.11, p = 0.008). Conclusions EUS-guided fine needle biopsy for small PNEN may be recommended to predict the malignant potential of the tumor by providing WHO classification.